Nabila I. Patel, DO – Clinical Research Experience

← Back to Our Team

Precision Research Center, Inc. · 2510 W Waters Ave, Tampa, FL 33614

Profile

Physician with experience as Principal Investigator and Sub-Investigator in industry-sponsored studies in metabolic, renal, respiratory, CNS, GI and infectious disease. Current ICH-GCP training.

Clinical Studies (2020–2026)

YearStudyClinicalTrials.gov
2026A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (Novartis CHDY015A12201)NCT07610278
2025A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435
2025Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsNCT06817889
2025Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionNCT06866236
2025A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female ParticipantsNCT06942936
2025A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation (GSK ENDURA, 222714)NCT06959095
2025A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional CohortNCT07024823
2025A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesNCT07030868
2025A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as Add-On Treatment in COPD Patients With Type 2 Inflammation (GSK Vigilant, 224295)NCT07177339
2025Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (Alnylam ALN-AGT01-008)NCT07181109
2025A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression (Boehringer Ingelheim 1378-0023)NCT06926660
2024A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression (Merck MK4482-023)NCT06667700
2024A Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Subjects with Major Depressive DisorderNCT06360419
2024Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNCT04838392
2024An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyNCT06534892
2023A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With Standard Risk for Developing Severe DiseaseNCT05715528
2023A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)NCT06011577
2023A randomized, double-blind, multicenter, phase III study to evaluate the long-term efficacy and safety of obefazimod 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitisNCT05535946
2023A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive SymptomsNCT06223880
2023A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)NCT05803421
2022Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)NCT05528861
2022A multicenter, randomized, double-blind, placebo-controlled 12-week study to evaluate the safety and efficacy of oral difelikefalin in advanced chronic kidney disease subjects with moderate-to-severe pruritus and not on dialysis with an up to 52-week long-term extension—
2022A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitisNCT05507203
2022A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease AgitationNCT05557409
2022Randomized, double-blind, placebo-controlled, parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney diseaseNCT05182840
2022An open-label, long-term extension study to evaluate the safety and tolerability of Simufilam 100 mg tablets in participants with mild to moderate Alzheimer’s diseaseNCT05575076
2022A 3-year, 3-group, preference, multi-center study to demonstrate the slowing of disease progression when switching from cigarette smoking to the Tobacco Heating System (THS) in mild to moderate Chronic Obstructive Pulmonary Disease (COPD) subjects with a history of chronic bronchitis symptomsNCT05569005
2022A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients with Treatment-Resistant DepressionNCT05113771
2022A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney DiseaseNCT05312879
2021A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)NCT04859517
2021A randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of intranasal STI-2099 (COVI-DROPS™) in outpatient adults with COVID-19NCT04906694
2021Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to dual combinations for the treatment of hypertension: An international, multi-center, randomized, double-blind, active-controlled, parallel-group trialNCT04518293
2021Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to placebo for the treatment of hypertension: An international, multi-center, randomized, double-blind, placebo-controlled, parallel-group trialNCT04518306
2021A Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Dose-escalation Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients with Major Depressive Disorder After Single Oral Dosing, Phase INCT04937829
2021A Phase 1b, Multiple Ascending Dose Trial Examining the Safety and Tolerability of Subcutaneous MANP in Difficult to Control/Resistant Hypertensive Subjects, Phase INCT05247528
2021A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100mg Tablets in Subjects with Mild to Moderate Alzheimer’s DiseaseNCT04994483
2021A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 76-week study evaluating the safety and efficacy of two doses of Simufilam in subjects with mild-to-moderate Alzheimer’s diseaseNCT05026177
2021Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety and Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years and Older with a History of Urinary Tract Infection in the Past 2 YearsNCT04899336
2021An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s TypeNCT04947553
2020A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for the Treatment of Confirmed COVID-19 in Outpatient (CAMostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 [CAMELOT])NCT04583592
2020A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2NCT04313023
2020A Phase II/III randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in nonhospitalized patientsNCT04545060
2020A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19NCT04625972
2020A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s typeNCT04408755

← Back to Our Team